Home › Diffuse Large B-Cell Lymphoma
Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma na nagre-recruit sa U.S.
101 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- New York City, NY21 pag-aaral
- Baldwin Park, CA19 pag-aaral
- Chicago, IL18 pag-aaral
- Houston, TX17 pag-aaral
- Los Angeles, CA17 pag-aaral
- Milwaukee, WI16 pag-aaral
- Boston, MA16 pag-aaral
- Philadelphia, PA15 pag-aaral
- Portland, OR15 pag-aaral
- Durham, NC14 pag-aaral
- Nashville, TN14 pag-aaral
- Dallas, TX13 pag-aaral
- Seattle, WA12 pag-aaral
- Salt Lake City, UT12 pag-aaral
- Washington, DC12 pag-aaral
- Cincinnati, OH11 pag-aaral
- Denver, CO11 pag-aaral
- Cleveland, OH11 pag-aaral
- Rochester, MN10 pag-aaral
- Columbus, OH10 pag-aaral
- Richmond, VA10 pag-aaral
- Edison, NJ9 pag-aaral
- Cedar Rapids, IA9 pag-aaral
- Omaha, NE9 pag-aaral
- Atlanta, GA9 pag-aaral
- Jacksonville, FL8 pag-aaral
- Grand Rapids, MI8 pag-aaral
- New Haven, CT8 pag-aaral
- Greenburgh, NY8 pag-aaral
- San Antonio, TX8 pag-aaral
- Sacramento, CA8 pag-aaral
- St. Louis, MO8 pag-aaral
- Louisville, KY8 pag-aaral
- San Francisco, CA8 pag-aaral
- Miami, FL7 pag-aaral
- Aurora, CO7 pag-aaral
- Kansas City, MO7 pag-aaral
- Charlottesville, VA7 pag-aaral
- Indianapolis, IN7 pag-aaral
- Pittsburgh, PA6 pag-aaral
Ayos sa estado
- Alabama4 pag-aaral
- Arizona13 pag-aaral
- Arkansas4 pag-aaral
- California43 pag-aaral
- Colorado19 pag-aaral
- Connecticut8 pag-aaral
- District of Columbia4 pag-aaral
- Florida23 pag-aaral
- Georgia14 pag-aaral
- Idaho4 pag-aaral
- Illinois22 pag-aaral
- Indiana9 pag-aaral
- Iowa11 pag-aaral
- Kansas7 pag-aaral
- Kentucky11 pag-aaral
- Louisiana6 pag-aaral
- Maryland13 pag-aaral
- Massachusetts16 pag-aaral
- Michigan15 pag-aaral
- Minnesota16 pag-aaral
- Missouri8 pag-aaral
- Montana4 pag-aaral
- Nebraska9 pag-aaral
- Nevada3 pag-aaral
- New Jersey13 pag-aaral
- New Mexico3 pag-aaral
- New York31 pag-aaral
- North Carolina20 pag-aaral
- North Dakota4 pag-aaral
- Ohio24 pag-aaral
- Oklahoma5 pag-aaral
- Oregon16 pag-aaral
- Pennsylvania19 pag-aaral
- South Carolina4 pag-aaral
- South Dakota4 pag-aaral
- Tennessee18 pag-aaral
- Texas29 pag-aaral
- Utah14 pag-aaral
- Virginia17 pag-aaral
- Washington17 pag-aaral
- Wisconsin19 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Nagre-recruitPhase 2
Edad 65 hanggang 99 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT05952024Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06977711Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06649812Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Nagre-recruitPhase 1/2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT03223610A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT03418038A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06890884A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05139017A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07519772A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06091865Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06784167A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06395103Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT05757219Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04002947A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT05272384Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07225439Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT06500273Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT06784726Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07365306Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07284433Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.